Abstract

INTRODUCTION

A subgroup of pT1cN0M0 breast cancer carries a high potential of relapse, and thus may require adjuvant chemotherapy. In this study, we aimed to identify the efficacy of adjuvant chemotherapy in patients with pT1cN0Mo breast cancer and the factors that may be prognostic prognostic factors

METHODS

Retrospective analysis of all patients with pT1c breast cancer, who underwent surgery from 1990 to 2013 at two centers. AC was partially standardized. (doxorubicin plus cyclophosphamide with or without taxan or 5-fluorouracil plus doxorubicin plus cyclophosphamide). Chi-square and Mann-Whitney U tests were used in the analysis of data. Statistical significance was accepted as p <0.05.

RESULTS

Two hundred and eighteen female patients only with T1cNoMo breast cancer met the eligibility criteria for this study. Despite the low incidence rate in our study, we identified 2 groups in which adjuvant chemotherapy was effective in univariate analysis. These groups were Her2 negative (p: 0.045) and Grade 2 (p: 0.033) groups. In multivariate analysis, HER-2 status and progesterone status were independent prognostic factors.

DISCUSSION AND CONCLUSION

Our findings imply that PR and HER-2 statuses had prognostic significance and adjuvant chemotherapy may offer adisease free survival advantage in some subgroups of T1c tumors. New prognostic and predictive tests are needed to better individualize the therapy and confine the systemic treatment.